Drug repositioning refers to the discovery of new indications for approved or failed drugs and the application of the newly identified drugs to the management of diseases other than the drug’s intended disease. It reduces the risk of developmental failure, cost, and time of development. In this review, candidate drugs identified so far based on drug repositioning for malignant glioma are summarized.
